Trial Profile

Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elagolix (Primary)
Indications Uterine leiomyoma
Focus Therapeutic Use
Sponsors AbbVie

Most Recent Events

08 May 2022 Results assessing efficacy and safety of Elagolix in women with uterine fibroids and heavy menstrual bleeding, presented at the 71st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
04 Mar 2022 Study phase changed from 3 to phase 4. Primary end-point has been amended.
30 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com